http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-030314-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a319cd672935a6d8b60f250121c9a4d0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q90-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-568 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
| filingDate | 2010-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb3ebaeda8adc14667b09858df1007dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39154a4ed5947b9912335807f521cb8b |
| publicationDate | 2018-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-030314-B1 |
| titleOfInvention | COMPOSITIONS FOR REDUCING THE CONTENT OF FAT |
| abstract | Pharmaceutical formulations with optimal dosage sizes are proposed that provide the maximum therapeutic effect for a patient, namely, a reduction in fat content, including a first version of a composition for reducing fat content, suitable for subcutaneous injection, containing (a) from 5 ng to 20 µg reducing adipose tissue a lipophilic selective beta-2 adrenergic receptor agonist of long-acting, selected from salmeterol, formoterol or their salts; and (b) a glucocorticosteroid selected from dexamethasone, prednisolone, fluticasone, budesonide, their salts or combinations thereof; (c) at least one inactive ingredient suitable for subcutaneous administration, wherein said inactive ingredient suitable for subcutaneous administration is selected from polysorbate-80 in an amount of from 0.01 to 10% or a cosolvent, such as polyethylene glycol, in an amount of from 0.25 to 40%, as well as the second variant of the composition, which differs from the first one in that it provides, upon subcutaneous administration, an average concentration of a lipophilic selective agonist of beta-2 long-acting adrenergic receptor C in plasma equal to or less than 300 pg / ml Moreover, the third variant of the composition is characterized in that the ratio of the selective agonist of beta-2 adrenergic receptor of long-acting and glucocorticosteroid is from 400: 1 to 1: 400, the fourth variant of the composition is characterized in that the ratio of selective agonist of beta-2 in adrenergic receptor of long-acting and glucocorticosteroid is from 200: 1 to 1: 200, and the fifth version of the composition includes the composition according to the first variant, in which the lipophilic selective beta-2 agonist of the long-acting adrenergic receptor The sixth version of the composition includes a composition according to any one of the first five variants of the composition, where the glucocorticosteroid is fluticasone propionate, and the seventh version of the composition includes a composition according to any one of the first six variants of the composition, in which the glucocorticosteroid is contained in an amount less than 1000 μg, the eighth the composition includes a composition according to any one of the first seven variants of the composition, intended for cosmetic reduction of the fat content of a person; the ninth version of the composition includes a composition according to To the boma of the first seven variants of the composition, designed to reduce fat in the waist area of a person, the tenth version of the composition includes a composition according to any of the first seven variants of the composition, for cosmetic reduction of waist size in humans, providing a waist reduction of at least 1 cm and, finally, The eleventh version of the composition includes a composition according to any one of the first seven variants of the composition, in which the glucocorticosteroid is contained in an amount of less than 25 μg. The mentioned compositions will find wide application for reducing the fat content of patients in need. |
| priorityDate | 2009-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 213.